MedTrace Logo

Alzheimer's Disease Research Center (ADRC) PET Component Study

NCT07758660 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-08-11

No results posted yet for this study

Summary

The purpose of this study is to further engage and characterize Alzheimer's Disease Research Center (ADRC) participants through additional research opportunities, particularly PET imaging. Amyloid and Tau PET imaging will be collected in 24 participants per year, for a total of 120 participants over five years.

All participants will be followed longitudinally, including through potential transitions from normal aging to mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD).

Conditions

Interventions

DRUG

18F-MK6240

MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.

DRUG

18F-Florbetaben (FBB)

Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Patrick Lao

    lead OTHER

Principal Investigators

  • Patrick J Lao, PhD · Columbia University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-06
Primary Completion
2031-05-31
Completion
2033-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07758660 on ClinicalTrials.gov